[go: up one dir, main page]

RU2018107330A - IMMUNITY INDUCTOR - Google Patents

IMMUNITY INDUCTOR Download PDF

Info

Publication number
RU2018107330A
RU2018107330A RU2018107330A RU2018107330A RU2018107330A RU 2018107330 A RU2018107330 A RU 2018107330A RU 2018107330 A RU2018107330 A RU 2018107330A RU 2018107330 A RU2018107330 A RU 2018107330A RU 2018107330 A RU2018107330 A RU 2018107330A
Authority
RU
Russia
Prior art keywords
polypeptides
provisions
amino acid
polypeptide
positions
Prior art date
Application number
RU2018107330A
Other languages
Russian (ru)
Other versions
RU2018107330A3 (en
RU2758112C2 (en
Inventor
Акира КУРИХАРА
Фумиёси ОКАНО
Original Assignee
Торэй Индастриз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Торэй Индастриз, Инк. filed Critical Торэй Индастриз, Инк.
Publication of RU2018107330A publication Critical patent/RU2018107330A/en
Publication of RU2018107330A3 publication Critical patent/RU2018107330A3/ru
Application granted granted Critical
Publication of RU2758112C2 publication Critical patent/RU2758112C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Claims (32)

1. Индуктор иммунитета, содержащий в качестве активного ингредиента следующие компоненты (i) или (ii):1. An immunity inducer containing, as an active ingredient, the following components (i) or (ii): (i) по меньшей мере, один полипептид, обладающий индуцирующей иммунитет активностью и выбранный из группы полипептидов (a) или (b), указанных ниже:(i) at least one polypeptide having immunity-inducing activity and selected from the group of polypeptides (a) or (b) indicated below: (a) полипептидов, состоящих из 7 или больше непрерывно следующих друг за другом аминокислот в области положений 24-97, положений 113-132, положений 134-197, положений 204-225, положений 265-332, положений 378-463, положений 472-498, положений 533-567, положений 613-643, положений 671-735, положений 737-780, положений 792-830, положений 832-899, положений 920-943, положений 946-993, положений 1029-1069 и положений 1074-1215 в аминокислотной последовательности, представленной в SEQ ID NO: 2;(a) polypeptides consisting of 7 or more amino acids continuously following each other in the field of positions 24-97, positions 113-132, positions 134-197, positions 204-225, positions 265-332, positions 378-463, positions 472 -498, Provisions 533-567, Provisions 613-643, Provisions 671-735, Provisions 737-780, Provisions 792-830, Provisions 832-899, PROVISIONS 920-943, PROVISIONS 946-993, PROVISIONS 1029-1069 AND PROVISIONS 1074 -1215 in the amino acid sequence shown in SEQ ID NO: 2; (b) полипептидов, содержащих от одной до нескольких аминокислотных делеций, замен и/или добавлений в аминокислотной последовательности любого из полипептидов (a);(b) polypeptides containing from one to several amino acid deletions, substitutions and / or additions in the amino acid sequence of any of the polypeptides (a); (ii) рекомбинантный вектор, содержащий, по меньшей мере, один полинуклеотид, кодирующий любой из полипептидов и способный экспрессировать полипептид in vivo.(ii) a recombinant vector containing at least one polynucleotide encoding any of the polypeptides and capable of expressing the polypeptide in vivo. 2. Индуктор иммунитета по п.1, в котором полипептид (i) связывается с молекулой MHC класса I.2. The immunity inducer according to claim 1, in which the polypeptide (i) binds to a class I MHC molecule. 3. Индуктор иммунитета по п.2, в котором полипептид (i) представляет собой любой полипептид, выбранный из группы полипептидов (c)-(e), указанных ниже:3. The immunity inducer according to claim 2, in which the polypeptide (i) is any polypeptide selected from the group of polypeptides (c) - (e) indicated below: (c) полипептидов, состоящих из аминокислотных последовательностей, представленных в SEQ ID NO: 3-34;(c) polypeptides consisting of the amino acid sequences shown in SEQ ID NO: 3-34; (d) полипептидов, содержащих от одной до нескольких аминокислотных делеций, замен и/или добавлений в аминокислотной последовательности любого из полипептидов (c);(d) polypeptides containing from one to several amino acid deletions, substitutions and / or additions in the amino acid sequence of any of the polypeptides (c); (e) полипептидов, каждый из которых содержит в качестве неполной последовательности любой из полипептидов (c) или (d).(e) polypeptides, each of which contains, as an incomplete sequence, any of the polypeptides (c) or (d). 4. Индуктор иммунитета по п.1, в котором полипептид (i) связывается с молекулой MHC класса II.4. The immunity inducer according to claim 1, in which the polypeptide (i) binds to the MHC class II molecule. 5. Индуктор иммунитета по п.4, в котором полипептидом (i) является любой из полипептидов, выбранных из группы полипептидов (f)-(h), указанных ниже:5. The immunity inducer according to claim 4, in which the polypeptide (i) is any of the polypeptides selected from the group of polypeptides (f) - (h) indicated below: (f) полипептидов, состоящих из аминокислотных последовательностей, представленных в SEQ ID NO: 35-67;(f) polypeptides consisting of the amino acid sequences shown in SEQ ID NO: 35-67; (g) полипептидов, содержащих от одной до нескольких аминокислотных делеций, замен и/или добавлений в аминокислотной последовательности любого из полипептидов (f);(g) polypeptides containing from one to several amino acid deletions, substitutions and / or additions in the amino acid sequence of any of the polypeptides (f); (h) полипептидов, каждый из которых содержит в качестве неполной последовательности любой из полипептидов (f) или (g).(h) polypeptides, each of which contains, as an incomplete sequence, any of the polypeptides (f) or (g). 6. Индуктор иммунитета по любому из пп.1-5, который применим в качестве активного ингредиента в средстве для лечения или профилактики злокачественной опухоли.6. The immunity inducer according to any one of claims 1 to 5, which is applicable as an active ingredient in an agent for treating or preventing a malignant tumor. 7. Индуктор иммунитета по п.6, в котором злокачественная опухоль представляет собой злокачественную опухоль, экспрессирующую белок PDS5A.7. The immunity inducer according to claim 6, in which the malignant tumor is a malignant tumor expressing the PDS5A protein. 8. Индуктор иммунитета по п.6 или 7, в котором злокачественной опухолью является лейкоз, злокачественная лимфома, рак простаты, рак печени, рак молочной железы, рак поджелудочной железы, рак яичника, рак почки, рак прямой и ободочной кишки, рак желудка, злокачественная опухоль головного мозга, рак легкого или рак пищевода.8. The immunity inducer according to claim 6 or 7, in which the malignant tumor is leukemia, malignant lymphoma, prostate cancer, liver cancer, breast cancer, pancreatic cancer, ovarian cancer, kidney cancer, colon and colon cancer, stomach cancer, a malignant brain tumor, lung cancer or cancer of the esophagus. 9. Индуктор иммунитета по любому из пп.1-8, дополнительно содержащий иммуностимулятор.9. The immunity inducer according to any one of claims 1 to 8, further comprising an immunostimulant. 10. Полипептид, обладающий индуцирующей иммунитет активностью и выбранный из группы полипептидов (a) или (b), указанных ниже:10. A polypeptide having immunity-inducing activity and selected from the group of polypeptides (a) or (b) below: (a) полипептидов, обладающих индуцирующей иммунитет активностью и состоящих из 7 или более непрерывно следующих друг за другом аминокислот в области положений 24-97, положений 113-132, положений 134-197, положений 204-225, положений 265-332, положений 378-463, положений 472-498, положений 533-567, положений 613-643, положений 671-735, положений 737-780, положений 792-830, положений 832-899, положений 920-943, положений 946-993, положений 1029-1069 и положений 1074-1215 в аминокислотной последовательности, представленной в SEQ ID NO: 2;(a) polypeptides having immunity-inducing activity and consisting of 7 or more amino acids continuously following each other in the range of positions 24-97, positions 113-132, positions 134-197, positions 204-225, positions 265-332, positions 378 -463, Provisions 472-498, Provisions 533-567, Provisions 613-643, Provisions 671-735, Provisions 737-780, Provisions 792-830, PROVISIONS 832-899, PROVISIONS 920-943, PROVISIONS 946-993, PROVISIONS 1029 -1069 and positions 1074-1215 in the amino acid sequence shown in SEQ ID NO: 2; (b) полипептидов, содержащих от одной до нескольких аминокислотных делеций, замен и/или добавлений в аминокислотной последовательности любого из полипептидов (a).(b) polypeptides containing from one to several amino acid deletions, substitutions and / or additions in the amino acid sequence of any of the polypeptides (a). 11. Полипептид по п.10, в котором полипептидом является любой полипептид, выбранный из группы полипептидов (c)-(e), указанных ниже:11. The polypeptide of claim 10, in which the polypeptide is any polypeptide selected from the group of polypeptides (c) - (e) indicated below: (c) полипептидов, состоящих из аминокислотных последовательностей, представленных в SEQ ID NO: 3-34;(c) polypeptides consisting of the amino acid sequences shown in SEQ ID NO: 3-34; (d) полипептидов, содержащих от одной до нескольких аминокислотных делеций, замен и/или добавлений в аминокислотной последовательности любого из полипептидов (c);(d) polypeptides containing from one to several amino acid deletions, substitutions and / or additions in the amino acid sequence of any of the polypeptides (c); (e) полипептидов, каждый из которых содержит в качестве неполной последовательности любой из полипептидов (c) или (d).(e) polypeptides, each of which contains, as an incomplete sequence, any of the polypeptides (c) or (d). 12. Полипептид по п.10, в котором полипептидом является любой полипептид, выбранный из группы полипептидов (f)-(h), указанных ниже:12. The polypeptide of claim 10, in which the polypeptide is any polypeptide selected from the group of polypeptides (f) - (h) indicated below: (f) полипептидов, состоящих из аминокислотных последовательностей, представленных в SEQ ID NO: 35-67;(f) polypeptides consisting of the amino acid sequences shown in SEQ ID NO: 35-67; (g) полипептидов, содержащих от одной до нескольких аминокислотных делеций, замен и/или добавлений в аминокислотной последовательности любого из полипептидов (f);(g) polypeptides containing from one to several amino acid deletions, substitutions and / or additions in the amino acid sequence of any of the polypeptides (f); (h) полипептидов, каждый из которых содержит в качестве неполной последовательности любой из полипептидов (f) или (g).(h) polypeptides, each of which contains, as an incomplete sequence, any of the polypeptides (f) or (g). 13. Изолированная антигенпрезентирующая клетка, содержащая комплекс полипептида, обладающего индуцирующей иммунитет активностью, по любому из пп.10-12 и молекулы MHC.13. An isolated antigen-presenting cell containing a complex of a polypeptide having immunity-inducing activity according to any one of claims 10-12 and an MHC molecule. 14. Изолированная T-клетка, которая избирательно связывается с комплексом полипептида, обладающего индуцирующей иммунитет активностью, по любому из пп.10-12 и молекулы MHC.14. An isolated T cell that selectively binds to a complex of a polypeptide having immunity-inducing activity according to any one of claims 10-12 and an MHC molecule.
RU2018107330A 2015-08-10 2016-08-05 Immunity inducer RU2758112C2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015158539 2015-08-10
JP2015-158539 2015-08-10
PCT/JP2016/073077 WO2017026389A1 (en) 2015-08-10 2016-08-05 Immunity inducer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2021127767A Division RU2835947C2 (en) 2015-08-10 2016-08-05 Immunity inducer

Publications (3)

Publication Number Publication Date
RU2018107330A true RU2018107330A (en) 2019-09-12
RU2018107330A3 RU2018107330A3 (en) 2020-01-31
RU2758112C2 RU2758112C2 (en) 2021-10-26

Family

ID=57984435

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018107330A RU2758112C2 (en) 2015-08-10 2016-08-05 Immunity inducer

Country Status (16)

Country Link
US (2) US11510971B2 (en)
EP (1) EP3335725B1 (en)
JP (1) JP7181676B2 (en)
KR (1) KR102679914B1 (en)
CN (1) CN107847573B (en)
AU (1) AU2016306408B2 (en)
BR (1) BR112018001542A2 (en)
DK (1) DK3335725T5 (en)
ES (1) ES2977955T3 (en)
FI (1) FI3335725T3 (en)
HU (1) HUE066530T2 (en)
MX (1) MX392412B (en)
PL (1) PL3335725T3 (en)
PT (1) PT3335725T (en)
RU (1) RU2758112C2 (en)
WO (1) WO2017026389A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017026389A1 (en) * 2015-08-10 2017-02-16 東レ株式会社 Immunity inducer
KR20230008254A (en) 2017-11-08 2023-01-13 바이오엔테크 유에스 인크. T cell manufacturing compositions and methods
AR118859A1 (en) * 2019-05-08 2021-11-03 Neon Therapeutics Inc COMPOSITIONS AND METHODS OF MANUFACTURING T CELLS
CN116139253B (en) * 2021-08-10 2025-04-22 昆明医科大学 A polypeptide capable of improving immunity, resisting tumors and prolonging life and its application

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997009065A1 (en) 1995-09-07 1997-03-13 Japan Tobacco Inc. Remedy for autoimmune disease
AU2002305151A1 (en) * 2001-04-06 2002-10-21 Georgetown University Gene scc-112 and diagnostic and therapeutic uses thereof
US7842467B1 (en) * 2005-05-12 2010-11-30 Celera Corporation Breast disease targets and uses thereof
JP5438676B2 (en) 2007-07-19 2014-03-12 ヘルス リサーチ インコーポレイテッド Survivin peptide as a cancer vaccine
WO2009054710A1 (en) 2007-10-23 2009-04-30 Villegas Lopez Saul Sanding device for cylindrical interiors and/or exteriors
CA2703350C (en) 2007-10-25 2018-02-20 Toray Industries, Inc. Immune response inducer
TWI580431B (en) 2008-08-19 2017-05-01 腫瘤療法 科學股份有限公司 HIG2 and URLC10 epitope peptides and vaccines containing the peptides
PL2474315T3 (en) 2009-09-03 2018-07-31 Toray Industries, Inc. IMMUNOLOGICAL RESPONSE INDUCTOR
JP5954175B2 (en) * 2011-05-19 2016-07-20 東レ株式会社 Immune inducer
JP5954174B2 (en) * 2011-05-19 2016-07-20 東レ株式会社 Immune inducer
WO2017026389A1 (en) * 2015-08-10 2017-02-16 東レ株式会社 Immunity inducer
US20190346442A1 (en) 2016-04-18 2019-11-14 The Broad Institute, Inc. Improved hla epitope prediction

Also Published As

Publication number Publication date
US11510971B2 (en) 2022-11-29
JP7181676B2 (en) 2022-12-01
HUE066530T2 (en) 2024-08-28
CN107847573B (en) 2021-12-31
WO2017026389A1 (en) 2017-02-16
EP3335725B1 (en) 2024-02-28
KR20180037999A (en) 2018-04-13
DK3335725T3 (en) 2024-04-02
MX2018001298A (en) 2018-05-17
US20180200356A1 (en) 2018-07-19
RU2018107330A3 (en) 2020-01-31
RU2758112C2 (en) 2021-10-26
JPWO2017026389A1 (en) 2018-05-24
AU2016306408B2 (en) 2021-02-11
ES2977955T3 (en) 2024-09-03
EP3335725A4 (en) 2019-03-27
FI3335725T3 (en) 2024-04-23
CA2993427A1 (en) 2017-02-16
BR112018001542A2 (en) 2018-11-06
AU2016306408A1 (en) 2018-02-22
PL3335725T3 (en) 2024-07-22
EP3335725A1 (en) 2018-06-20
CN107847573A (en) 2018-03-27
US20230190899A1 (en) 2023-06-22
DK3335725T5 (en) 2024-10-07
MX392412B (en) 2025-03-24
RU2021127767A (en) 2021-11-23
PT3335725T (en) 2024-05-08
KR102679914B1 (en) 2024-07-01

Similar Documents

Publication Publication Date Title
SA522433360B1 (en) Modified L-Asparaginase
MX2023001394A (en) Optimized factor viii genes.
EP4223772A3 (en) Optimized factor viii gene
HRP20240495T1 (en) Anti-garp antibody
PE20180505A1 (en) PEPTIDES AND COMBINATION OF PEPTIDES AND NOVEL SCAFFOLDINGS FOR USE IN IMMUNOTHERAPY AGAINST RENAL CELL CARCINOMA (RCC) AND OTHER CANCERS
RU2018107330A (en) IMMUNITY INDUCTOR
PH12016501623A1 (en) Compositions for the inactivation of virus replication and methods of making and using the same
TN2019000015A1 (en) Bispecific antibody-like binding proteins specifically binding to cd3 and cd123
WO2017015630A3 (en) Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
MX2017016101A (en) Adenovirus polynucleotides and polypeptides.
JP2017524380A5 (en) Tumor vascular blocker polypeptide, gene, expression vector, tumor vascular blocker composition, and method for preparing polypeptide as tumor vascular blocker
PH12019500306B1 (en) Malignant tumor target peptide
AR099068A1 (en) ANTI-NETRINA-1 ANTIBODY
WO2016004906A3 (en) Tumor vascular disrupting agent polypeptide, gene, expression vector, and use thereof
MX2016011637A (en) Methods and compositions for secretion of heterologous polypeptides.
TN2017000520A1 (en) Compositions and methods for treating celiac sprue disease
MX2021015766A (en) Novel cancer antigens and methods.
AR101101A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING A THERAPEUTIC AGENT BASED ON RECOMBINANT HEMOGLOBIN PROTEIN OR SUBUNITY FOR TREATMENT DIRECTED TO CANCER
EP4461371A3 (en) Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers
WO2021062389A3 (en) Peptide for treating cancer
RU2021113516A (en) COMBINED THERAPY USING REIC / Dkk-3 GENE AND AN IMMUNE RESPONSE POINT INHIBITOR
RU2013156409A (en) AGENT INDUCING IMMUNITY
RU2006119452A (en) RECOMBINANT PROTEIN POSSESSING ANTI-CANCER ACTION, ENCODING ITS GENE AND ITS APPLICATION
RU2013156368A (en) IMMUNITY INDUCTION PRODUCT
RU2018134171A (en) IMMUNITY INDUCTOR